Biotech

Update

Biotech

Gene editing, mRNA, and pharma innovation. CRSP/TMO are entry zones. IBRX/NTLA/MRNA ran too hard.

Quick Snapshot

Signal Reading
Overall 🟡 Mixed - Half the list just ran 30-195%. CRSP/TMO are real pullbacks.
Key insight IBRX +195%, NTLA +39%, MRNA +32% = FOMO TRAPS. CRSP -7% is actual entry.

Action Matrix

Action Stocks Why
✅ STRONG BUY CRSP -7% pullback, Casgevy approved, gene editing leader
🔍 WATCH TMO -5% dip, steady compounder, lab tools
🔍 WATCH LLY, VRTX Sideways/steady, expensive but quality
⚠️ AVOID IBRX, NTLA, MRNA Ran 32-195%, wait for pullback

Legend

  • RSI ↓ = Oversold (<30) - potential buying opportunity
  • RSI ↑ = Overbought (>70) - FOMO warning, may pullback
  • 52wkHi = % from 52-week high (how far below peak)

Data

Stock Price 1D 7D 30D 3M 52wkHi RSI Status Action
LLY $1,043.58 - - +0% - - - 🟡 Sideways 🔍 Watch
TMO $581.92 - - -5% - - - 🟢 Pullback 🔍 Watch
IBRX $6.14 - - +195% - - - 🔴 Ran ⚠️ Avoid
MRNA $42.54 - - +32% - - - 🔴 Ran ⚠️ Avoid
CRSP $51.32 - - -7% - - - 🟢 Pullback ✅ Strong Buy
NTLA $13.02 - - +39% - - - 🔴 Ran ⚠️ Avoid
VRTX $471.97 - - +5% - - - 🟡 Steady 🔍 Watch

News Summary

LLY - Eli Lilly

Date Headline Sentiment
2026-01-28 "2026 Will Be the Year of Eli Lilly" - Nasdaq 🟢 Bullish
2026-01-29 Price target $1,251 (P/E 50, EPS $25) 🟢 Bullish
2026-01-23 Soared 39% in 2025 🟢 Bullish

TMO - Thermo Fisher

Date Headline Sentiment
2026-01-30 Q4 beat: $12.22B revenue, $6.57 EPS 🟢 Bullish
2026-01-24 Strategic collaboration with NVIDIA 🟢 Bullish

IBRX - ImmunityBio

Date Headline Sentiment
2026-01-30 Extends rally after FDA talks 🟢 Bullish
2026-01-27 700% Anktiva sales jump, time to book profits? 🟡 Caution

MRNA - Moderna

Date Headline Sentiment
2026-02-02 Stock falls amid market uptick 🔴 Bearish

CRSP - CRISPR Therapeutics

  • Casgevy approved and commercial
  • Pipeline: CTX310, CTX320, SRSD107

NTLA - Intellia

  • NTLA-2002 filing expected 2H 2026
  • +39% run without us

Analysis

LLY - Eli Lilly

Thesis: GLP-1/obesity drug leader. Mounjaro, Zepbound.

  • Price: $1,043.58
  • 30D: +0.25% (sideways)
  • Largest pharma by market cap
  • Premium valuation (~50x earnings)
  • GLP-1 thesis playing out but priced in

Verdict: 🔍 Watch - great company, expensive stock, wait for dip

TMO - Thermo Fisher Scientific

Thesis: Lab equipment and life sciences tools. Picks & shovels for biotech.

  • Price: $581.92
  • 30D: -4.82% (pullback)
  • Q4 beat expectations
  • NVIDIA AI collaboration
  • Steady compounder

Verdict: 🔍 Watch - dip is interesting, boring but works

IBRX - ImmunityBio

Thesis: Cancer immunotherapy platform. ANKTIVA drug.

  • Price: $6.14
  • 30D: +194.71% (!!!)
  • 700% Anktiva sales jump
  • FDA resubmission path advancing
  • BUT: +195% = CLASSIC FOMO TRAP

Verdict: ⚠️ AVOID - thesis may be right but +195% is insane, wait for pullback

MRNA - Moderna

Thesis: mRNA platform beyond COVID.

  • Price: $42.54
  • 30D: +32.27%
  • Beaten down from 2021 highs ($449)
  • Pipeline diversification underway
  • BUT: +32% in 30D = FOMO territory

Verdict: ⚠️ AVOID - recovery may be real but already ran, wait

CRSP - CRISPR Therapeutics

Thesis: First approved CRISPR therapy (Casgevy for sickle cell).

  • Price: $51.32
  • 30D: -6.96% (PULLBACK!)
  • Casgevy approved and commercial with Vertex
  • Pipeline: CTX310, CTX320, SRSD107
  • Gene editing market projected $30B+ by 2032
  • THIS is the entry the others missed

Verdict: ✅ STRONG BUY - only gene editing pullback, thesis intact

NTLA - Intellia Therapeutics

Thesis: In vivo CRISPR editing leader.

  • Price: $13.02
  • 30D: +39.38%
  • NTLA-2002 filing expected 2H 2026
  • In vivo approach vs CRSP's ex vivo
  • BUT: +39% = missed it

Verdict: ⚠️ AVOID - earlier stage than CRSP AND already ran

VRTX - Vertex Pharmaceuticals

Thesis: Cystic fibrosis dominance + CRISPR partnership.

  • Price: $471.97
  • 30D: +5.17% (steady)
  • CF franchise is cash cow
  • Partnered with CRSP on Casgevy
  • Lower risk than pure-play gene editing

Verdict: 🔍 Watch - established, steady, less exciting

The Gold

Key Discoveries

Discovery Implication
IBRX +195% in 30D Classic FOMO trap - 700% sales ≠ 700% more upside
CRSP is ONLY pullback Gene editing entry exists, but only CRSP
MRNA +32% after being "beaten down" Recovery play already recovered
TMO + NVIDIA collaboration AI in lab equipment is real theme
NTLA +39% without us Waited too long on gene editing

Mistakes

Mistake Lesson
Didn't buy IBRX before +195% Thesis research took too long
Didn't buy NTLA before +39% Same pattern as BE, EOSE
Didn't buy MRNA before +32% "Beaten down" stocks can run fast

Open Questions

  • Is CRSP the right gene editing entry?
  • Will IBRX/NTLA/MRNA pull back to entry?
  • Is LLY ever cheap enough to buy?
  • Does TMO dip further?

Next Actions

  • Research CRSP Casgevy sales trajectory
  • Set IBRX alert at $4 (35% pullback)
  • Set NTLA alert at $9 (30% pullback)
  • Set MRNA alert at $32 (25% pullback)
  • Monitor TMO for further dip to $550
10 events
DateTypeEvent
Feb 4 ScanBiotech Scan Feb 4 UpdateBiotech Feb 1 UpdatePortfolio - Main Snapshot Feb 5 ScanBiotech Scan Mar 10 ScanBiotech Scan Mar 11 ScanInsider Activity Scan Mar 11 ScanBiotech Scan Mar 12 UpdateBiotech Mar 12 ScanBiotech Scan Apr 3 UpdateBiotech Candidates

No direct external sources are attached to this read.